立方制药公告，公司与葵花药业集团佳木斯鹿灵制药有限公司签订了《美沙拉秦肠溶片MAH转让合 同》，决定以3400万元转让美沙拉秦肠溶片药品的所有权。 ...

Core Viewpoint - The company announced that its wholly-owned subsidiary, Luling Kewhua, has acquired the marketing authorization and related production technology for Mesalazine enteric-coated tablets (0.5g specification) from Lifan Pharmaceutical for 34 million yuan (including tax) [1] Group 1: Transaction Details - The acquisition involves a change of the marketing authorization holder, which requires approval from the National Medical Products Administration [1] - The transaction does not constitute a related party transaction or a major asset restructuring [1] - The payment for the contract is divided into three installments, and the contract is valid until the marketing authorization holder is changed to Luling Kewhua and the production site is changed or increased to a designated site, completing verification of three batches of production and passing inspection [1] Group 2: Strategic Implications - The transaction aims to implement the "One Elderly" strategy, enrich the product pipeline, and strengthen the company's advantage in gastrointestinal medications [1]

Group 1 - The Anhui Provincial Health Commission and other authorities have released the first batch of "new quality drug and medical device" product catalog to accelerate the promotion and application of innovative medical products, fostering new productive forces in the biopharmaceutical industry [1] - A total of 60 "new quality drug and medical device" products were announced, with 45 products from Hefei, accounting for 75% of the total in the province, highlighting Hefei's strong innovation capabilities and industrial clustering effect [1] - In the biopharmaceutical sector, all three selected biopharmaceuticals in the province are from Hefei, including innovative drugs for tuberculosis/influenza prevention by Zhifei Longcom and anti-tumor drugs by Anke Bio [1] Group 2 - Hefei's Industrial and Information Technology Bureau is actively promoting the innovative development of the biopharmaceutical industry, focusing on building a collaborative industrial ecosystem involving government, industry, academia, research, application, and finance [2] - The city is nurturing local leading enterprises such as Anke Bio, Opcon Vision, and Meiya Optoelectronics while successfully attracting innovative companies like Ruisi Digital Technology through high-level platforms [2] - Collaboration with institutions like the University of Science and Technology of China and Anhui University of Traditional Chinese Medicine has led to the incubation of technology-based SMEs, creating a favorable development pattern for large, medium, and small enterprises [2]

合肥立方制药股份有限公司 2025年中期权益分派实施公告 证券代码：003020 证券简称：立方制药 公告编号：2025-075 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 合肥立方制药股份有限公司（以下简称"公司"）2025 年中期权益分派方 案已获 2025 年 11 月 17 日召开的 2025 年第二次临时股东会审议通过，现将权 益分派事宜公告如下： 一、股东会审议通过利润分配方案情况 1、公司于2025年11月17日召开2025年第二次临时股东会，审议通过了《关 于2025年中期利润分配预案的议案》。公司2025年中期权益分派方案为：拟以 实施权益分派股权登记日的总股本为基数分配利润，公司拟向全体股东每10股 派发现金红利人民币2.00元（含税），以此初步计算，公司拟派发现金红利合 计人民币38,036,436.40元（含税）。本次利润分配不送红股，不以资本公积转 增股本。 2、自上述权益分派方案披露至实施期间，公司股本总额未发生变化。截至 目前，公司总股本为190,182,182股。 3、公司总股本发生变动的，按照每股分配比例不变的原则，相应调 ...

Core Viewpoint - Company received acceptance notification for drug registration applications for Dapagliflozin Metformin Extended-Release Tablets (I, II, III) from the National Medical Products Administration [1] Company Summary - Dapagliflozin Metformin Extended-Release Tablets are a fixed-dose combination formulation consisting of SGLT2 inhibitor Dapagliflozin and the biguanide drug Metformin [1] - The combination aims to provide comprehensive and effective blood glucose control for adult patients with type 2 diabetes [1] Industry Summary - The product is co-developed by Bristol-Myers Squibb Company and AstraZeneca AB [1] - As of the announcement date, eight domestic companies have received approval for similar products, excluding imported ones [1]

Core Viewpoint - The company, Lianfang Pharmaceutical, has received a notice of acceptance for the drug registration application of Dapagliflozin Metformin Extended-Release Tablets from the National Medical Products Administration, indicating progress in bringing this combination diabetes medication to market [1] Group 1: Product Details - Dapagliflozin Metformin Extended-Release Tablets are a fixed-dose combination formulation that includes Dapagliflozin, an SGLT2 inhibitor, and Metformin, a biguanide, which work synergistically to control blood sugar levels [1] - Dapagliflozin lowers blood sugar by promoting urinary glucose excretion, while Metformin primarily reduces hepatic glucose output and improves insulin sensitivity [1] - This combination aims to provide more comprehensive and effective blood sugar control for adult patients with type 2 diabetes [1] Group 2: Market Context - The product is co-developed by Bristol-Myers Squibb Company and AstraZeneca AB, indicating a collaboration between major pharmaceutical companies [1] - As of the date of the announcement, eight other companies have received approval for similar products in the domestic market, highlighting competitive dynamics in the diabetes medication sector [1]

Core Viewpoint - The company, Lifan Pharmaceutical, has received the acceptance notice for the drug registration application of Dapagliflozin Metformin Extended-Release Tablets from the National Medical Products Administration, indicating progress in bringing this combination diabetes medication to market [1] Group 1: Product Details - Dapagliflozin Metformin Extended-Release Tablets are a fixed-dose combination formulation that includes the SGLT2 inhibitor Dapagliflozin and the biguanide Metformin, which work synergistically to control blood sugar levels [1] - Dapagliflozin lowers blood sugar by promoting urinary glucose excretion, while Metformin primarily reduces hepatic glucose output and improves insulin sensitivity [1] - This combination aims to provide more comprehensive and effective blood sugar control for adult patients with type 2 diabetes [1] Group 2: Market Context - The product is co-developed by Bristol-Myers Squibb and AstraZeneca, highlighting collaboration between major pharmaceutical companies in the diabetes treatment space [1] - As of the announcement date, there are eight domestic companies that have received approval for similar products, indicating a competitive market landscape for diabetes medications in China [1]

证券代码：003020 证券简称：立方制药 公告编号：2025-076 合肥立方制药股份有限公司 关于收到药品注册受理通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 近日，合肥立方制药股份有限公司（以下简称"公司"或"立方制药"）收到 国家药品监督管理局下发的达格列净二甲双胍缓释片（I）、达格列净二甲双胍缓释 片（II）及达格列净二甲双胍缓释片（III）药品注册上市许可申请《受理通知书》。 现将相关情况公告如下： 一、《受理通知书》主要内容 申请事项：境内生产药品注册上市许可 三、对公司的影响及风险提示 达格列净二甲双胍缓释片注册上市许可申请获得受理，表示该品种进入注册审 1 评阶段，对公司短期业绩不会产生重大影响。如该品种顺利通过注册审评，将进一 步丰富公司产品线，提升公司市场竞争力。由于相关产品的注册批准文件取得时间 和结果均具有不确定性，敬请广大投资者谨慎决策，注意投资风险。 特此公告。 合肥立方制药股份有限公司 董事会 2025年11月22日 | 产品名称 | 规格 | 受理号 | | --- | --- | --- | | 达格列净二甲 ...

Meeting Overview - The second extraordinary general meeting of Hefei Lifan Pharmaceutical Co., Ltd. was held on November 17, 2025, with a combination of on-site and online voting methods [3][8] - The meeting was convened by the company's board of directors and presided over by Chairman Ji Junqiu [4][5] Attendance and Voting - A total of 189 shareholders and their proxies attended the meeting, representing 120,229,876 shares, which is 63.2183% of the total voting shares [6] - Among them, 13 shareholders attended the meeting on-site, representing 106,381,385 shares (55.9366%), while 175 shareholders participated via online voting, representing 13,848,491 shares (7.2817%) [6] - Small and medium-sized shareholders accounted for 16,452,031 shares (8.6507%) of the total voting shares [7] Resolutions and Legal Compliance - No proposals were rejected during the meeting, and it did not involve changes to previously approved resolutions [8] - The meeting's procedures were confirmed to comply with the Company Law of the People's Republic of China and the company's articles of association, as verified by the witnessing lawyers [9] Documentation - The resolutions from the meeting and the legal opinion from Beijing Jingtian & Gongcheng Law Firm are available for review [10]

证券代码：003020 证券简称：立方制药 公告编号：2025-074 合肥立方制药股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决提案的情形。 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、召开时间 （1）现场会议召开时间：2025 年 11 月 17 日（星期一）下午 15:00； 2、现场会议召开地点：安徽省合肥市文曲路 446 号科研综合楼五楼会议中 心。 （2）网络投票时间： 通过深圳证券交易所交易系统投票的时间为：2025 年 11 月 17 日 9:15—9:25、 9:30—11:30、下午 13:00—15:00； 通过深圳证券交易所互联网投票系统投票的时间为：2025 年 11 月 17 日 9:15 —15:00。 3、会议召开方式：现场投票与网络投票相结合的方式。 4、会议召集人：公司董事会。 5、会议主持人：公司董事长季俊虬先生。 6、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规、规范性文件 ...